Novartis (NYSE:NVS) said today that a committee for the European Medicines Agency has recommended that the regulatory agency approve Aimovig, a self-administered drug designed to prevent migraines in adults who have at least four migraine days each month.
The drug is the first of a new class of medicines, called CGRP inhibitors. It’s a monoclonal antibody that blocks the receptor for a protein that is linked to migraine pain, known as the calcitonin gene-related peptide. Just last month Aimovig, developed by Amgen (NSDQ:AMGN), won FDA approval in the U.S.
Get the full story at our sister site, Drug Delivery Business News.